Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Cost of Revenue (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Cost of Revenue data on record, last reported at $1.8 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 44.9% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $7.0 million, up 69.75%, while the annual FY2025 figure was $7.0 million, 69.75% up from the prior year.
  • Cost of Revenue reached $1.8 million in Q4 2025 per TLSI's latest filing, up from -$3.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $15.0 million in Q4 2023 and bottomed at -$3.5 million in Q3 2025.
  • Average Cost of Revenue over 4 years is $2.6 million, with a median of $1.2 million recorded in 2024.
  • The widest YoY moves for Cost of Revenue: up 685.42% in 2025, down 444.12% in 2025.
  • A 4-year view of Cost of Revenue shows it stood at $701000.0 in 2022, then surged by 2041.37% to $15.0 million in 2023, then plummeted by 91.9% to $1.2 million in 2024, then soared by 44.9% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $1.8 million in Q4 2025, -$3.5 million in Q3 2025, and $7.2 million in Q2 2025.